Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

24-07-22	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
21-12-09	TearLab Corporation Announces Board Appointments	CI
21-12-09	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
21-11-09	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
21-09-16	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
20-07-28	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
20-07-08	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
20-07-08	TearLab Corporation to Seek Acquisitions	CI
20-06-26	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-05-11	TearLab Corporation Announces Board Appointments	CI
20-05-11	Tearlab Mulls Inorganic Growth Opportunities	CI
20-05-10	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
20-05-10	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

20-07-09	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-26	TearLab: 1Q Earnings Snapshot	AQ
20-06-26	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
20-06-08	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
20-05-29	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Benjamin D. Sullivan CTO	Chief Tech/Sci/R&D Officer	-	2009-07-16
Adam Szaronos CEO	Chief Executive Officer	-	2026-03-31
John Lund DFI	Director of Finance/CFO	60	2022-06-30

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	2020-07-08
James V. Mazzo CHM	Chairman	68	2021-12-08
Richard Lindstrom BRD	Director/Board Member	78	2004-08-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
20-07-08	Elias Vamvakas	Tender	Chief Executive Officer	182,953	0.7495%
20-07-08	Paul M. Karpecki	Tender	Director	102,200	0.4187%
20-07-08	Anthony Altig	Tender	Director	10,499	0.0430%

TearLab Corporation Stock

Stocks

Medical Equipment, Supplies & Distribution

Latest news : TearLab Corporation

Press Releases: TearLab Corporation

Managers and Directors: TearLab Corporation

Latest insider transactions

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEARLAB CORPORATION	-.--%	+2.84%	-	-	1.41M
ESSILORLUXOTTICA	-2.28%	-5.01%	-27.93%	+3.03%	91.51B
ALCON INC.	+1.85%	-0.56%	-24.68%	-26.71%	31.92B
THE COOPER COMPANIES, INC.	+1.32%	-2.90%	-5.12%	-28.58%	12.85B
LENSKART SOLUTIONS LIMITED	+1.37%	+3.61%	-	-	9.42B
SHANGHAI CONANT OPTICAL CO., LTD.	-2.85%	-2.85%	+4.55%	+619.39%	2.32B
AUTEK CHINA INC.	-1.52%	-2.56%	-24.83%	-63.67%	1.46B
MINGYUE OPTICAL LENS CO.,LTD.	-1.69%	-0.47%	-34.10%	-30.46%	878M
PEGAVISION CORPORATION	+5.14%	+3.15%	+10.46%	-5.89%	795M
MENICON CO., LTD.	+0.81%	-1.16%	+51.82%	-36.68%	748M
Average	+0.22%	-0.86%	-6.23%	+53.80%	16.88B
Weighted average by Cap.	-0.83%	-3.17%	-23.99%	+2.43%